Session » Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: PsA
- 2:00PM-3:30PM
-
Abstract Number: 0780
Assessing Differential Effects of DMARDs on Psoriasis Area and Severity Index and Patient Global Assessment in Subgroups of Patients with Active PsA Treated over 52-weeks with Secukinumab in a Non-Interventional Trial (AQUILA) Using a Multistage Clustering Approach
- 2:00PM-3:30PM
-
Abstract Number: 0777
Characteristics of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis
- 2:00PM-3:30PM
-
Abstract Number: 0775
Effectiveness of Dose Reduction and Withdrawal Strategies of TNF Inhibitors in Psoriatic Arthritis and Axial Spondyloarthritis: Long Term Extension of the DRESS-PS Study
- 2:00PM-3:30PM
-
Abstract Number: 0776
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study
- 2:00PM-3:30PM
-
Abstract Number: 0779
Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)
- 2:00PM-3:30PM
-
Abstract Number: 0778
The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial